Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A
Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients' health in China. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company's products under development include small RNA drugs, such as FB7011/FB7013/FB7014 to treat IgA ne… Read more
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221) - Net Assets
Latest net assets as of June 2025: CN¥1.04 Billion CNY
Based on the latest financial reports, Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221) has net assets worth CN¥1.04 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.66 Billion) and total liabilities (CN¥619.25 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.04 Billion |
| % of Total Assets | 62.77% |
| Annual Growth Rate | 13.6% |
| 5-Year Change | -46.68% |
| 10-Year Change | N/A |
| Growth Volatility | 107.84 |
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A - Net Assets Trend (2019–2024)
This chart illustrates how Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (2019–2024)
The table below shows the annual net assets of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.14 Billion | -15.00% |
| 2023-12-31 | CN¥1.34 Billion | -19.67% |
| 2022-12-31 | CN¥1.67 Billion | -8.68% |
| 2021-12-31 | CN¥1.83 Billion | -14.50% |
| 2020-12-31 | CN¥2.14 Billion | +255.00% |
| 2019-12-31 | CN¥602.99 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 137789786832.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥3.10 Billion | 271.42% |
| Total Equity | CN¥1.14 Billion | 100.00% |
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
JOHNSON SVC. LS-10
F:5K7
|
$548.86 Million |
|
Eastman Kodak Co
NYSE:KODK
|
$548.99 Million |
|
Alerus Financial Corp
NASDAQ:ALRS
|
$549.02 Million |
|
Grocery Outlet Holding Corp
NASDAQ:GO
|
$549.10 Million |
|
STAAR Surgical Company
NASDAQ:STAA
|
$548.73 Million |
|
Universal Health Realty Income Trust
NYSE:UHT
|
$548.70 Million |
|
Raffles Medical Group Ltd
F:02M1
|
$548.22 Million |
|
Xiamen Port Development Co Ltd
SHE:000905
|
$548.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,342,682,087 to 1,141,311,397, a change of -201,370,691 (-15.0%).
- Net loss of 201,382,610 reduced equity.
- Dividend payments of 14,909,561 reduced retained earnings.
- Other factors increased equity by 14,921,481.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-201.38 Million | -17.64% |
| Dividends Paid | CN¥14.91 Million | -1.31% |
| Other Changes | CN¥14.92 Million | +1.31% |
| Total Change | CN¥- | -15.00% |
Book Value vs Market Value Analysis
This analysis compares Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.24x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 8.50x to 6.24x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥2.23 | CN¥19.00 | x |
| 2020-12-31 | CN¥5.96 | CN¥19.00 | x |
| 2021-12-31 | CN¥5.09 | CN¥19.00 | x |
| 2022-12-31 | CN¥4.46 | CN¥19.00 | x |
| 2023-12-31 | CN¥3.58 | CN¥19.00 | x |
| 2024-12-31 | CN¥3.05 | CN¥19.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -17.64%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -155.54%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.59x
- Recent ROE (-17.64%) is above the historical average (-20.06%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -31.92% | -922.58% | 0.02x | 1.56x | CN¥-252.73 Million |
| 2020 | -10.77% | -494.89% | 0.02x | 1.18x | CN¥-445.04 Million |
| 2021 | -14.21% | -642.07% | 0.02x | 1.38x | CN¥-443.08 Million |
| 2022 | -21.34% | -421.01% | 0.04x | 1.44x | CN¥-523.91 Million |
| 2023 | -24.50% | -287.93% | 0.05x | 1.59x | CN¥-463.23 Million |
| 2024 | -17.64% | -155.54% | 0.07x | 1.59x | CN¥-315.51 Million |
Industry Comparison
This section compares Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221) | CN¥1.04 Billion | -31.92% | 0.59x | $548.84 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |